Dr. Hani Hassoun, MD

Dr. Hassoun practices at Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center.

Dr. Hassoun's NPI, 1285605220, was assigned on January 29, 2006. Dr. Hassoun graduated from Pierre and Marie Curie University in 1983. Dr. Hassoun holds New York license 224714.

Dr. Hassoun's primary practice is Memorial Sloan Kettering Cancer Center, at 1275 York Avenue, New York, NY 10065.

Dr. Hassoun's primary practice is Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center. The medical group on file is Memorial Hematology Lymphoma Group. Dmand AI also links Dr. Hassoun to 3 more group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Hassoun practices, 4 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Hassoun's primary specialty in the NPI Registry, under taxonomy code 207RH0000X. The record also lists hematology. Dr. Hassoun is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Hassoun's licenses on file in 2 states: New York and New Jersey.

Dmand AI lists breast cancer, lung cancer, multiple myeloma, prostate cancer and purpura and thrombocytopenia among the conditions Dr. Hassoun treats.

CMS data shows 749 Medicare services from Dr. Hassoun across 6 procedure codes in 2024, for 272 Medicare patients. Medicare paid $71,273 for them.

CMS counts 272 Medicare patients who saw Dr. Hassoun in 2024. The largest group is 65 to 74, with 127 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 14% are also on Medicaid. Their average risk score is 2.59, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Hassoun's median patient age at 74, with 48% women.

In 2024, Dr. Hassoun wrote 1,159 Medicare Part D claims for 163 patients. 74% of them were for generic drugs. CMS names the drug for 1,043 of them, across 18 drugs with 11 or more claims each, at $6,896,629 in total drug cost. In 2023, CMS named 722 claims across 13 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 80 out of 100 for Dr. Hassoun for performance year 2024, reported as part of a group. Dr. Hassoun accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Hassoun as offering telehealth.

Dmand AI links 124 papers to Dr. Hassoun, published from 2003 to 2025. 2020 was the busiest year, with 11. The most frequent topics are Multiple Myeloma, Antineoplastic Combined Chemotherapy Protocols and Dexamethasone. Dr. Hassoun has published most often in Leuk Lymphoma. Dr. Hassoun's most frequent co-authors are Alexander M. Lesokhin, MD, Sergio A. Giralt, MD and Neha Korde, MD.

Dmand AI links Dr. Hassoun to 13 clinical trials, 9 of them phase 2 studies. 3 are still active or recruiting. Conditions studied include Multiple Myeloma, Blood Protein Disorders and Immunoglobulin Light-chain Amyloidosis. Memorial Sloan Kettering Cancer Center sponsors the most, 8.

CMS Open Payments shows 12 general payments to Dr. Hassoun from 8 drug and device companies from 2016 to 2023. Consulting fees make up the largest share, 72% of the total. Takeda Pharmaceuticals U.S.A., Inc. paid the most, $2,338. It also lists 1 research payment totaling $3,621 in 2019.

Dmand AI lists 1 award for Dr. Hassoun, most recently Top Doctors: New York Metro Area in 2014.

Dr. Hassoun graduated from Pierre and Marie Curie University in 1983.

Dr. Hassoun is in network with 13 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.